Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients

Table 2 Cox proportional-hazards model for mortality in patients treated with immune checkpoint inhibitors

Variables	Hazard ratio for mortality	P value
Thyroid irAE compared to no thyroid irAE	0.417 (0.238—0.729)	0.002
Types of thyroid dysfunction ^a
Newly developed overt hypothyroidism (N = 38)	0.327 (0.160—0.667)	0.002
Worsened hypothyroidism (N = 4)	0.599 (0.138—2.599)	0.493
Subclinical hyperthyroidism (N = 16)	0.607 (0.254—1.4048)	0.260
Male compared to female	0.963 (0.580—1.601)	0.886
Nivolumab ^b	1.189 (0.724 – 1.952)	0.493
Atezolizumab ^b	1.739 (0.719 – 4.206)	0.220

ISSN: 1472-6823